Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.
ADT
ARSi
PSMA-PET
RECIP
Journal
European journal of hybrid imaging
ISSN: 2510-3636
Titre abrégé: Eur J Hybrid Imaging
Pays: England
ID NLM: 101724113
Informations de publication
Date de publication:
02 Oct 2023
02 Oct 2023
Historique:
received:
18
07
2023
accepted:
06
09
2023
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
1
10
2023
Statut:
epublish
Résumé
To evaluate whether quantitative whole-body (WB) PSMA-PET metrics under long-term androgen deprivation therapy (ADT) and/or androgen receptor signaling inhibitors (ARSi) are associated with PSA progression. Patients who underwent at least 2 Thirty-five patients were included: 12/35 (34%) were treated with ADT only and 23/35 (66%) with ARSi ± ADT. The median time between PET1 and PET2 was 539 days. Changes (%) in median PSA levels, WB-PSMA-SUV Changes in PSA correlated with changes observed on PSMA-PET, although discordance between PSA and PSMA-PET changes was observed. Further research is necessary to evaluate if PSMA-PET parameters can predict progression-free survival and overall survival and serve as novel endpoints in clinical trials.
Identifiants
pubmed: 37779132
doi: 10.1186/s41824-023-00178-1
pii: 10.1186/s41824-023-00178-1
pmc: PMC10542625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
© 2023. Springer Nature Switzerland AG.
Références
Afshar-Oromieh A, Debus N, Uhrig M et al (2018) Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 45:2045–2054
doi: 10.1007/s00259-018-4079-z
pubmed: 29980832
pmcid: 6182397
Aggarwal R, Wei X, Kim W et al (2018) Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 1:78–82
doi: 10.1016/j.euo.2018.03.010
pubmed: 31100231
Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433
doi: 10.1056/NEJMoa1405095
pubmed: 24881730
pmcid: 4418931
Calais J, Kishan AU, Cao M et al (2018) Potential impact of (68)Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 59:1714–1721
doi: 10.2967/jnumed.118.209387
pubmed: 29653978
pmcid: 6225538
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
doi: 10.1056/NEJMoa1014618
pubmed: 21612468
pmcid: 3471149
Eiber M, Herrmann K, Calais J et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478
doi: 10.2967/jnumed.117.198119
pubmed: 29123012
Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856–863
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829
Fizazi K, Tran N, Fein L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686–700
doi: 10.1016/S1470-2045(19)30082-8
pubmed: 30987939
Gafita A, Bieth M, Kronke M et al (2019) qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET/CT. J Nucl Med 60:1277–1283
doi: 10.2967/jnumed.118.224055
pubmed: 30850484
pmcid: 6735278
Gafita A, Rauscher I, Weber M et al (2022a) Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 63:1651–1658
pubmed: 35422442
pmcid: 9635677
Gafita A, Rauscher I, Fendler WP et al (2022b) Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging 49:4271–4281
doi: 10.1007/s00259-022-05882-x
pubmed: 35767071
Hoberuck S, Lock S, Winzer R et al (2020) [(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Res 10:135
doi: 10.1186/s13550-020-00723-0
pubmed: 33159278
pmcid: 7647983
Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
Hope TA, Truillet C, Ehman EC et al (2017) 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 58:81–84
doi: 10.2967/jnumed.116.181800
pubmed: 27660139
pmcid: 5209643
Lutje S, Slavik R, Fendler W, Herrmann K, Eiber M (2017) PSMA ligands in prostate cancer—probe optimization and theranostic applications. Methods 130:42–50
doi: 10.1016/j.ymeth.2017.06.026
pubmed: 28666778
Onal C, Guler OC, Torun N, Reyhan M, Yapar AF (2020) The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 47:632–641
doi: 10.1007/s00259-019-04581-4
pubmed: 31732768
Oruc Z, Guzel Y, Ebinc S et al (2021) Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. Nucl Med Commun 42:1336–1346
doi: 10.1097/MNM.0000000000001464
pubmed: 34366407
Plouznikoff N, Artigas C, Sideris S et al (2019) Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med 33:945–954
doi: 10.1007/s12149-019-01404-2
pubmed: 31587172
Rosset A, Spadola L, Ratib O (2004) OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging 17:205–216
doi: 10.1007/s10278-004-1014-6
pubmed: 15534753
pmcid: 3046608
Schaeffer E, Srinivas S, Antonarakis ES et al (2021) NCCN guidelines insights: prostate cancer, version 1. 2021. J Natl Compr Canc Netw. 19:134–143
doi: 10.6004/jnccn.2021.0008
pubmed: 33545689
Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402–1418
doi: 10.1200/JCO.2015.64.2702
pubmed: 26903579
pmcid: 4872347
Seifert R, Herrmann K, Kleesiek J et al (2020) Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med 61:1786–1792
doi: 10.2967/jnumed.120.242057
pubmed: 32332147
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
pubmed: 9815541
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
doi: 10.3322/caac.21660
pubmed: 33538338
The Jamovi Project [computer program]. Version 1.6.23: Jamovi; 2021
Tombal B, Borre M, Rathenborg P et al (2014) Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 15:592–600
doi: 10.1016/S1470-2045(14)70129-9
pubmed: 24739897
Tseng JR, Chang SH, Wu YY et al (2022) Impact of three-month androgen deprivation therapy on [68Ga]Ga-PSMA-11 PET/CT indices in men with advanced prostate cancer-results from a pilot prospective study. Cancers 14:1329
doi: 10.3390/cancers14051329
pubmed: 35267637
pmcid: 8909781
Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9–15
doi: 10.1007/s00259-019-04529-8
pubmed: 31654093
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
doi: 10.2967/jnumed.108.057307
pubmed: 19403881
Zukotynski KA, Emmenegger U, Hotte S et al (2021) prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted (18)F-DCFPyL PET/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide. J Nucl Med 62:1430–1437
doi: 10.2967/jnumed.120.259069
pubmed: 33608426
pmcid: 8724901